ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 3,120,000 shares, an increase of 7.2% from the March 15th total of 2,910,000 shares. Currently, 11.5% of the company’s shares are short sold. Based on an average daily volume of 389,200 shares, the short-interest ratio is presently 8.0 days.

ALX Oncology Trading Up 6.4 %

Shares of ALXO traded up $0.82 during mid-day trading on Tuesday, reaching $13.71. The stock had a trading volume of 564,779 shares, compared to its average volume of 396,102. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. ALX Oncology has a 52-week low of $3.94 and a 52-week high of $17.42. The business’s fifty day moving average is $13.52 and its 200 day moving average is $11.77. The firm has a market cap of $687.56 million, a price-to-earnings ratio of -3.44 and a beta of 1.58.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, sell-side analysts predict that ALX Oncology will post -3.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ALXO. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Friday. Stifel Nicolaus reissued a “hold” rating and set a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of ALX Oncology in a research report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, ALX Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $18.83.

Insider Activity

In other news, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total value of $223,000.00. Following the completion of the sale, the insider now owns 628,359 shares in the company, valued at approximately $7,006,202.85. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the transaction, the insider now owns 628,359 shares in the company, valued at approximately $7,006,202.85. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jason Lettmann acquired 4,400 shares of ALX Oncology stock in a transaction that occurred on Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, with a total value of $49,764.00. Following the purchase, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The disclosure for this purchase can be found here. Company insiders own 50.30% of the company’s stock.

Institutional Trading of ALX Oncology

Several hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its holdings in ALX Oncology by 42.6% in the fourth quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after acquiring an additional 684 shares in the last quarter. Credit Suisse AG raised its holdings in ALX Oncology by 6.6% during the second quarter. Credit Suisse AG now owns 15,157 shares of the company’s stock worth $121,000 after purchasing an additional 940 shares in the last quarter. American International Group Inc. raised its holdings in ALX Oncology by 14.1% during the second quarter. American International Group Inc. now owns 10,040 shares of the company’s stock worth $81,000 after purchasing an additional 1,237 shares in the last quarter. Swiss National Bank raised its holdings in ALX Oncology by 8.5% during the first quarter. Swiss National Bank now owns 19,200 shares of the company’s stock worth $324,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in ALX Oncology during the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.